General Announcement::Glenmark Pharmaceuticals receives ANDA approval for Bisoprolol Fumarate & Hydrochlorothiazide Tablet

Issuer & Securities

Issuer/ Manager
GLENMARK PHARMACEUTICALS LIMITED
Securities
GLENMARK PHARM US$170M2%220628 - XS1426780125 - 4G8B
Stapled Security
No

Announcement Details

Announcement Title
General Announcement
Date &Time of Broadcast
27-Jan-2022 13:38:37
Status
New
Announcement Sub Title
Glenmark Pharmaceuticals receives ANDA approval for Bisoprolol Fumarate & Hydrochlorothiazide Tablet
Announcement Reference
SG220127OTHRUVO1
Submitted By (Co./ Ind. Name)
Glenmark Pharmaceuticals Limited
Designation
Company Secretary & Compliance Officer
Effective Date and Time of the event
27/01/2022 00:00:00
Description (Please provide a detailed description of the event in the box below)
Glenmark Pharmaceuticals receives ANDA approval for Bisoprolol Fumarate and Hydrochlorothiazide Tablets USP, 2.5 mg/6.25 mg, 5 mg/6.25 mg, and 10 mg/6.25 mg.